OptiNose to Present at the 35th Annual Cowen Healthcare Conference

Cowen Health Care Conference 2015

YARDLEY, Pa.--()--OptiNose today announced that the company will present at the 35th annual Cowen Healthcare Conference. CEO Peter Miller will discuss the Company's recent milestones, pipeline and strategy for 2015.

Miller will present on Monday, March 2, 2015 at 10:30 a.m. in the MIT Room on the 3rd Floor at the Boston Marriott Copley Place.

About OptiNose

OptiNose is a Specialty Pharmaceutical Company developing a promising pipeline of late stage new products. The Company’s patented Bi-Directional™ Breath Powered™ technology platform creates differentiated treatments by enabling deep intranasal drug deposition. OptiNose successfully out-licensed a first product at the end of phase 3 (AVP-825 for Migraine, licensed to AVNR in North America), and has proven clinical success with other products, including OPN-375, a treatment for Chronic Nasal Inflammatory Diseases (CNID) that will soon complete Phase 3. OPN-375 has the potential to be a breakthrough that creates a new standard of care for the treatment of serious CNID, such as Chronic Sinusitis. Other OptiNose pipeline products also target large and attractive markets with significant unmet need, including nose-to-brain technology applications such as OPN-300 for Autism. OptiNose has corporate offices in the US, Norway and the UK. For more information, please visit www.optinose.com.

About OptiNose’s Bi-Directional™ Breath Powered™ Delivery Technology

OptiNose's patented closed-palate Bi-Directional Breath Powered delivery technology is unique in that it uses the natural function of a user’s breath to propel medications beyond the nasal valve into the deep, targeted areas of the nasal cavity more effectively and efficiently than current treatment approaches. A user exhales into the device, creating a natural closure of the soft palate and sealing off the nasal cavity completely. The exhaled breath carries medication from the device into one side of the nose through a specially shaped sealing nosepiece, balancing the pressure on the soft palate. Narrow nasal passages are gently expanded and medication is transported well beyond the nasal valve to targeted sites. After delivering medication to the targeted sites, air flows around to the opposite side of the nasal cavity and exits through the other side of the nose rather than into the throat or lungs.

Contacts

Sloane & Company for OptiNose
Kate Traynor, 212-446-1871
Ktraynor@sloanepr.com

Recent Stories

RSS feed for OptiNose